Cargando…
Loading, please waitCargando…
Loading, please waitCondition Guide
A clear, conservative look at mesenchymal stem cell (MSC) therapy as a regenerative option for chronic obstructive pulmonary disease (COPD), delivered in Cancún, México under COFEPRIS oversight. What the published clinical evidence shows, what it does not yet show, who is and is not a candidate, and how the Regeneris pathway — free medical evaluation followed by a personalized written quote — actually works.
Mesenchymal stem cell (MSC) therapy for COPD (chronic obstructive pulmonary disease) is investigational, not an approved cure. The published clinical evidence — including a placebo-controlled randomized trial of allogeneic MSCs (Weiss et al., Chest 2013) and a Phase 1 autologous bone-marrow + adipose-derived stem cell trial (Squassoni et al., Int J COPD 2021) — reports a favorable safety profile and signals of reduced systemic inflammation, but no consistent reversal of lung-function decline. Regeneris Therapy in Cancún, México offers physician-led evaluation under COFEPRIS oversight, no published prices, and a personalized written quote only after a free medical evaluation. COPD is a progressive, multi-system disease — regenerative therapy is considered as an adjunct to, never a replacement for, GOLD-guideline-directed pulmonology care.
Clinical overview
Chronic obstructive pulmonary disease (COPD) is, in the 2023 GOLD definition, a heterogeneous lung condition characterized by chronic respiratory symptoms — dyspnea, cough, sputum production, and exacerbations — due to abnormalities of the airways (chronic bronchitis, bronchiolitis) and/or the alveoli (emphysema) that cause persistent, often progressive airflow obstruction. It is one of the top three causes of death worldwide and affects roughly 10% of the adult population aged 30–79. The disease reflects cumulative gene-environment exposures across a lifetime — tobacco smoke, biomass and occupational dust, ambient air pollution, and accelerated lung aging. A thorough medical workup is the first step at our Cancún clinic — long before any regenerative protocol is discussed.
Progressive destruction of the alveolar walls reduces the surface area available for gas exchange. Patients are typically older, thinner, and dyspneic, with hyperinflation on imaging. This is the phenotype most often discussed in MSC trial design because the lost alveolar surface is, in theory, what regenerative repair would need to address.
Chronic productive cough with airway inflammation, mucus hypersecretion, and recurrent exacerbations. Standard care leans heavily on bronchodilators, inhaled corticosteroids in selected cases, mucolytics, and exacerbation prevention — regenerative therapy is considered only as a supervised adjunct, never a replacement.
Many patients combine both phenotypes, and a subset overlap with asthma or have α1-antitrypsin deficiency, post-infectious damage, or vaping-related injury. These distinctions matter, because they shape the GOLD treatment group, the expected trajectory, and whether an investigational regenerative discussion is even reasonable.
COPD is a symptom complex with several biologic drivers. A serious evaluation in Cancún looks at the whole picture — pulmonary function testing, imaging, exacerbation history, comorbidities, oxygen needs, and smoking-cessation status — before MSC therapy is even considered for your specific case.
What the research shows
"Stem cell therapy for COPD" is not one evidence category. Published human work to date consists mostly of small Phase 1–2 trials and a placebo-controlled randomized Phase 2 study. The consistent finding is that systemic MSC administration is generally well tolerated; the inconsistent finding is whether it produces durable improvements in lung function. We report that gradient honestly here, rather than implying the therapy is approved or curative for COPD.
Weiss and colleagues randomized 62 patients with moderate-to-severe COPD across six sites to four monthly IV infusions of allogeneic bone-marrow-derived MSCs (Prochymal) or vehicle, with two years of follow-up. No serious or clinically significant adverse events were observed across 248 total infusions. The trial did not demonstrate significant improvements in lung function or quality-of-life endpoints, but reported an early, significant decrease in circulating C-reactive protein in MSC-treated patients with elevated baseline CRP — an anti-inflammatory signal that motivates ongoing investigation.
Squassoni and colleagues conducted a Phase 1 randomized trial in 20 COPD patients divided into four arms: control, autologous bone-marrow mononuclear cells (BMMC), adipose-derived mesenchymal stromal cells (ADSC), and co-infusion of both. No adverse events were attributable to cell therapy over 12 months of follow-up. The co-infusion arm reported the most promising signals on gas exchange and quality of life, and the BMMC arm showed lung-function improvements — both warranting larger Phase 3 confirmation rather than supporting routine clinical use today.
A 2021 review of MSC therapy for COPD synthesized eight completed clinical trials and found that allogeneic and autologous BM-MSC administration was safe with no serious adverse events attributable to therapy. Lung-function gains were limited (measurable improvement in only 2 of 8 trials, both with small samples), while 6 of 8 trials reported quality-of-life improvements that the authors note may reflect anti-inflammatory effects or placebo signal. C-reactive protein reductions were a recurring finding — consistent with the paracrine/immunomodulatory mechanism MSCs are understood to act through.
The founder of the field reframed MSCs as "medicinal signaling cells," arguing that their therapeutic effect comes chiefly from secreted bioactive factors — exosomes, growth factors, cytokines — that modulate inflammation and stimulate resident progenitor cells, rather than from engraftment and direct alveolar regeneration. For COPD this matters: the realistic short-term target of MSC therapy is dampening systemic and lung inflammation, not regrowing lost alveoli.
The honest read: the evidence is encouraging on safety and on the anti-inflammatory signal (lower CRP, improved quality-of-life scores in several studies), while still inconclusive on durable lung-function reversal. MSC therapy for COPD at Regeneris in Cancún is offered investigationally, under physician supervision, with that uncertainty explicitly disclosed — never as a guaranteed cure.
Candidate screening
Candidacy for an MSC protocol for COPD is decided in the medical evaluation, not on a website. The lists below describe the kinds of cases where a regenerative discussion is reasonable, and the situations where therapy is deferred or declined. They are general orientation — your physician in Cancún confirms or rules things out based on your actual pulmonology workup.
If any of the deferral situations applies to you, it does not necessarily rule therapy out forever — it means the next step is medical optimization with your treating pulmonologist, not an infusion.
Regulation & location
Regeneris Therapy operates in Cancún, Quintana Roo, México, under the federal oversight of COFEPRIS — Mexico's health regulatory authority, the functional equivalent of the U.S. FDA. Regenerative protocols including MSC therapy are delivered as physician-supervised, investigational care within that legal framework. There is no "stem-cell tourism" loophole here: the same federal rules that apply to a major hospital apply to our Cancún clinic.
Clinic operating notice on file with COFEPRIS (Aviso Sanitario 2323025036X00098) — the federal authorization framework under which advertised regenerative procedures may be offered in Cancún.
Advertising notice on file (Aviso de Publicidad 2323022002A00053) — meaning regenerative therapy information presented to patients in Cancún is registered with the regulator, not unregulated marketing.
Care is delivered in person at our Cancún, México facility — never as a remote prescription, mail-order kit, or unsupervised stack. International patients travel to Cancún for evaluation and treatment.
Choosing a clinic in Cancún, México does not mean choosing less oversight — it means choosing physician-led, COFEPRIS-regulated regenerative care delivered in a recognized medical-tourism city with strong logistics for patients from the U.S. and Canada.
How we work
There is no published price for MSC therapy for COPD on this page, in any brochure, or over the phone — because there is no honest fixed price. Cell source, dose, route, number of applications, and concomitant pulmonary care all depend on your evaluation. Our model is a free medical evaluation in Cancún (in person or by secure tele-consult for international patients), followed by a personalized written quote only if and when a protocol is recommended.
Send your history, recent spirometry (FEV1, FEV1/FVC, DLCO if available), chest imaging, exacerbation history, current inhaler regimen, oxygen status, and medication list. A licensed physician at our Cancún clinic reviews the case and either recommends a protocol, recommends further pulmonology workup, or honestly tells you regenerative therapy is not the right tool for you.
If a protocol is appropriate, you receive a written quote with the cell source, dose, route (typically systemic intravenous infusion for COPD), number of applications, and the medical reasoning behind each. No price appears until your case has been individually reviewed — never before.
Treatment is delivered at our Cancún facility under physician supervision, with vital-sign monitoring during infusion and structured follow-up that includes symptom scores (CAT, mMRC), 6-minute walk testing when indicated, spirometry, and continued coordination with your home pulmonologist.
If a clinic quotes you a price for stem cell therapy for COPD before reviewing your case, that is a marketing decision, not a medical one. Regeneris does the opposite, by design, in Cancún.
Honest expectations
The single most important thing on this page: MSC therapy for COPD is investigational. The published clinical signal at six months is a favorable safety profile and reductions in systemic inflammation (CRP), with mixed and modest effects on lung function. We frame outcomes that way deliberately — overpromising is both unethical and a violation of the COFEPRIS advertising framework we work under in Cancún.
Honest framing protects you: it lets you decide based on the actual evidence, not on a sales pitch. That is the standard we hold ourselves to in Cancún.
FAQ
The questions patients ask us most when considering stem cell therapy for COPD at our Cancún, México clinic.
No. Mesenchymal stem cell (MSC) therapy for COPD (chronic obstructive pulmonary disease) is investigational, not an approved cure. The published clinical evidence — including the placebo-controlled randomized trial by Weiss et al. (Chest, 2013) and the Phase 1 autologous co-infusion trial by Squassoni et al. (Int J COPD, 2021) — supports a favorable safety profile and an anti-inflammatory signal (reduced C-reactive protein in some patients), but does not demonstrate durable reversal of lung-function decline. We discuss it as a regenerative option that may help in well-selected cases, layered on top of guideline-directed pulmonology care, never as a guaranteed cure, at our Cancún clinic.
Delivery is physician-led under COFEPRIS oversight in Cancún, México. The route most commonly studied and used is systemic intravenous infusion of allogeneic mesenchymal stem cells, given over a defined protocol (one to four sessions in most trials). Cell source, dose, and sequence are individualized in your evaluation — there is no fixed package. Treatment is always preceded by spirometry, imaging review, and a full medical workup, and is followed by structured follow-up including symptom scores and continued coordination with your pulmonologist.
Not yet. MSC therapy is never offered as a substitute for smoking cessation or removing biomass/occupational exposure — those are the drivers of lung damage in COPD, and treating around them is not honest medicine. We require a documented cessation plan (or established cessation) and remediation of ongoing exposure before discussing a regenerative protocol. Our physicians can coordinate cessation support and refer you to validated programs as part of your evaluation in Cancún.
Regeneris does not publish prices for stem cell therapy — not for COPD, not for any indication. The reason is medical and ethical: cell source, dose, route, number of applications, and any concomitant care all depend on your individual evaluation, so a fixed online price would either misrepresent the case or pressure a sale. Our model is a free medical evaluation in Cancún (in person or by secure tele-consult), followed by a personalized written quote only if a protocol is recommended.
When responses are reported in the published literature, they are typically measured over weeks to months — symptom scales (CAT, mMRC), 6-minute walk distance, and quality-of-life questionnaires are the most commonly reported endpoints, with CRP reductions detectable earlier. Durability beyond 12–24 months is an open question with limited long-term data. We discuss your expected timeline honestly in the evaluation in Cancún, including what we can and cannot predict for your specific case.
Across the placebo-controlled randomized trial by Weiss et al. (Chest, 2013) and the Phase 1 trial by Squassoni et al. (Int J COPD, 2021), no serious adverse events were attributed to MSC therapy. The Weiss trial documented 248 infusions across 62 patients without infusional toxicity or treatment-related deaths. That said, MSC therapy is investigational, individual risk depends on your overall cardiopulmonary picture, and our Cancún physicians screen carefully for contraindications — active malignancy, recent exacerbation, unstable cardiovascular disease, active infection — before recommending any protocol. Anyone telling you the therapy is risk-free is overstating the evidence.
Continue exploring
The full pillar on mesenchymal stem cell therapy at Regeneris in Cancún: cell sources, mechanism, protocols, and how to start.
ContinueHow COFEPRIS oversight, lab certification, and physician supervision shape what "safe" means for regenerative care in Cancún.
ContinueTravel, logistics, and what international patients should know before coming to Cancún for stem-cell evaluation.
ContinueA 2026 comparison of regulation, available cell types, and travel logistics for cross-border regenerative care.
ContinueTalk to our medical team in Cancún. Free medical evaluation first, personalized written quote second — never the other way around.
ContinueThis page is informational and does not constitute medical advice. Mesenchymal stem cell therapy for COPD (chronic obstructive pulmonary disease) is investigational; outcomes vary by patient, disease stage, and protocol, and no regenerative therapy is a guaranteed cure for COPD. Treatment decisions require an individualized evaluation with a licensed physician at our Cancún clinic; disclose all current medications, oxygen requirements, and pulmonary history. Regeneris Therapy operates under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053 in Cancún, México.
Book a free 15-min call with our team.
Send your spirometry, imaging, exacerbation history, and current inhaler regimen. A physician at our Cancún clinic will review your case and tell you honestly whether stem cell therapy fits — with a personalized written quote after your free medical evaluation.